• Indaptus Therapeutics posted a first-quarter net loss of USD 2.54 million, narrowing from USD 4.53 million a year earlier; loss per share improved to USD 0.23 from USD 9.11.
• Research and development expense fell to 491,134 from USD 2.81 million a year earlier, due to lower Phase 1 clinical costs and reduced payroll tied to headcount and salary cuts.
• Cash and cash equivalents dropped to USD 1.5 million at March 31 from USD 8.51 million at Dec. 31; net cash used in operating activities increased to USD 7.01 million from USD 5.05 million.
• Management said it is reassessing development priorities and evaluating the Decoy platform’s preclinical data and scientific rationale, while reviewing operating initiatives, resource allocation, financing alternatives, and strategic options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150700PRIMZONEFULLFEED9721059) on May 15, 2026, and is solely responsible for the information contained therein.